Cristina Ortiz, "Moving forward", 2014, mixed technique, 120 cm x 70 cm, from the exhibition "Aspirations"
### Sunday, June 4, 2017 13:30-15:00

<table>
<thead>
<tr>
<th>Hall 10.A</th>
<th>Baxter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hall N103-104</td>
<td>Fresenius Medical Care</td>
</tr>
<tr>
<td>Hall N101-102</td>
<td>Amgen (Europe) GmbH</td>
</tr>
<tr>
<td>Hall N105-106</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Hall 10.B</td>
<td>Vifor Fresenius Medical Care Renal Pharma</td>
</tr>
<tr>
<td>Sala Retiro</td>
<td>B.Braun Avitum</td>
</tr>
<tr>
<td>Hall N107-108</td>
<td>Sanofi Genzyme</td>
</tr>
<tr>
<td>Sala Colon</td>
<td>Toray Medical</td>
</tr>
<tr>
<td>Hall N117-118</td>
<td>MSD</td>
</tr>
</tbody>
</table>

### 18:45-19:45

<table>
<thead>
<tr>
<th>Hall 10.B</th>
<th>Vifor Fresenius Medical Care Renal Pharma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hall N107-108</td>
<td>Baxter</td>
</tr>
<tr>
<td>Sala Neptuno</td>
<td>Sigma-Tau</td>
</tr>
<tr>
<td>Hall N117-118</td>
<td>NxStage Medical Inc</td>
</tr>
</tbody>
</table>

### Monday, June 5, 2017 13:30-15:00

<table>
<thead>
<tr>
<th>Hall 10.A</th>
<th>Vifor Fresenius Medical Care Renal Pharma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hall N103-104</td>
<td>Baxter</td>
</tr>
<tr>
<td>Hall N101-102</td>
<td>Alexion Pharmaceuticals Inc</td>
</tr>
<tr>
<td>Hall N105-106</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Hall 10.B</td>
<td>Shire International GmbH</td>
</tr>
<tr>
<td>Sala Retiro</td>
<td>PACE- Resverlogix</td>
</tr>
<tr>
<td>Hall N107-108</td>
<td>Danone Nutricia Research</td>
</tr>
<tr>
<td>Sala Colon</td>
<td>Otsuka Pharmaceutical Europe Ltd</td>
</tr>
<tr>
<td>Sala Neptuno</td>
<td>Nipro Medical Europe</td>
</tr>
</tbody>
</table>
Advancing Renal Therapies Through HDx (Expanded Hemodialysis)

Program

Introduction and welcome

ESRD, inflammation and cardiovascular outcomes: unwelcome triad
Chris McIntyre

Large middle molecules: the missing link?
Colin Hutchison

Expanded hemodialysis: advancing outcomes and care in renal therapies
Claudio Ronco

Panel discussion and Q&A

Summary and close

Industry Symposium

Sunday 4 June 2017
13:45–14:45
Hall 10.A
IFEMA – Feria de Madrid

Lunch will be provided at 13:30

Program start time: 13:45
Program duration: 60 minutes

Scientific Chair
Mario Cozzolino
Italy

Faculty
Chris McIntyre
Canada
Colin Hutchison
New Zealand
Claudio Ronco
Italy
Orchestrating Electrolytes Prescription in Hemodialysis To Improve Outcome

Fresenius Medical Care Scientific Symposium

June 4th, 2017, 13:30 – 15:00
at the 54th ERA-EDTA Congress, Madrid
Venue: Hall N 103-104

Sodium Dialysate: Finding the right balance
Carlo Basile (Italy)

Bicarbonate and Potassium: Fine-tuning the interaction
Jeroen Kooman (The Netherlands)

Citrate, Calcium and Magnesium: Setting the tone
Lucile Mercadal (France)

Chairmen
Alejandro Martin-Malo (Spain), Manfred Hecking (Austria)
Etelcalcetide: A new treatment option in the management of SHPT in haemodialysis patients

Sunday, 4th June, 13:30 – 15:00
54th ERA-EDTA Congress, Madrid | Spain
IFEMA Feria de Madrid, Hall N 101-102, Level 1
Chairman: Jordi Bover, Barcelona | Spain

Programme:
13:30 Lunch
13:45 Scientific programme starts
14:45 Scientific programme ends

Welcome and Introduction
Jordi Bover
Barcelona | Spain

Management of CKD-MBD: New evidence supporting the KDIGO guideline update
David Wheeler
London | United Kingdom

Treatment of SHPT with the injectable etelcalcetide
Markus Ketteler
Coburg | Germany

Este medicamento no está comercializado en España.
This medicinal product is not marketed in Spain.
Hyperkalaemia in CKD: An Evolving Treatment Landscape

Sunday, 4th June 2017
13:30–15:00
Hall N105–106

The objectives of this educational event are to help delegates understand:

1) The burden of illness of hyperkalaemia in patients with chronic kidney disease (CKD)
2) The risk of cardiac abnormalities and mortality that hyperkalaemia gives rise to in patients with CKD, and how these can be managed
3) The potential of current and investigative therapies to maintain normokalaemia in patients with renal disease

**Agenda**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–14:00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14:00–14:10</td>
<td>Chair’s Introduction</td>
<td>David Packham</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Australia)</td>
</tr>
<tr>
<td>14:10–14:30</td>
<td>Hyperkalaemia and Its Role in Cardiac Outcomes in Patients with CKD</td>
<td>Ziad Massy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(France)</td>
</tr>
<tr>
<td>14:30–14:50</td>
<td>Is the Way We Manage Hyperkalaemia Evolving?</td>
<td>Alan Jardine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(UK)</td>
</tr>
<tr>
<td>14:50–15:00</td>
<td>Panel Q&amp;A / Discussion</td>
<td>All</td>
</tr>
</tbody>
</table>

The ‘Hyperkalaemia in CKD: An Evolving Treatment Landscape’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The ‘Hyperkalaemia in CKD: An Evolving Treatment Landscape’ is designated for a maximum of 1 hour of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme. Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Supported by an unrestricted educational grant from AstraZeneca.
Dear Colleague

It gives me great pleasure to welcome you to this Vifor Fresenius Medical Care Renal Pharma-sponsored symposium, entitled ‘Is there a role for iron beyond erythropoiesis in patients with chronic kidney disease?’

I am honoured to be joined by such an esteemed faculty of nephrologists and cardiologists to provide our expert perspective on the scientific and clinical data supporting the benefits of treating iron deficiency before the onset of anaemia. These benefits extend beyond the standard practice correction of haemoglobin levels, and intravenous iron treatment is associated with significant improvements in symptom severity, functional capacity and quality of life.

While the current evidence base supporting these non-haematological benefits of iron therapy lies within the cardiology setting, evidence is lacking in the nephrology setting. There is overlap between the patients treated by cardiologists and those treated by nephrologists, and we wish to consider how the evidence from cardiology studies can be interpreted by the nephrologist. However, the ability of iron therapy to alleviate symptoms and/or functional capacity is unlikely to be restricted to this overlapping patient pool, and we also wish to discuss which other groups of chronic kidney disease patients suffering from iron deficiency could benefit from iron treatment.

This promises to be an engaging and stimulating educational session. I encourage you to participate in the discussions; alternatively, questions can be submitted by completing the question cards provided and handing them to an organizer during the symposium.

Professor Danilo Fliser
Chair
Sunday, June 4th
01:30 pm – 03:00 pm
Sala Retiro

MULTI-TARGETED APPROACH TO INCREASE HEMODIALYSIS EFFICIENCY

PROGRAM & SPEAKERS

Is hemodialysis technique of relevance for CKD-MBD?
Marc Vervoet, Amsterdam, NL

The role of gut microbiota in kidney disease
Pieter Evenepoel, Leuven, BE

Innovations in dialysis
Antonio Santoro, Bologna, IT

CHAIR
Àngel Argilés, Montpellier, FR
SATELLITE SYMPOSIUM

FABRY DISEASE: PRACTICAL QUESTIONS IN DECISION MAKING

Chair: Prof. Alberto Ortiz

Renal phenotype-to-genotype correlation issues
Prof. João-Paulo Oliveira - Portugal

Renal biopsies in clinical decision making
Prof. Einar Svarstad - Norway

ERT: when to treat and which outcome to expect
Prof. Alberto Ortiz - Spain

LUNCH TO BE PROVIDED

PLEASE VISIT OUR BOOTH 4.015
Novel clinical potential of adsorptive dialysis membrane

Date: Sunday, June 4th, 2017 13:30 – 15:00
Room: Sala Colò

Hemodialysis is associated with a number of long-term comorbidities, among which chronic inflammation and cardiovascular risk. Traditional hemodialysis membranes work by either diffusion or convection or a combination of the two, by which small and middle molecules can be removed effectively. By adding a third dimension – adsorption – also larger molecules and protein bound uremic toxins (PBUTs) can be removed. Dialysis membranes in polymethylmetacrylate (PMMA), in addition to having adsorptive capabilities, are also well known for their outstanding biocompatibility.

In this symposium Professor Panichi will talk about SC4D0L and its role as predictive marker of cardiovascular morbidity and mortality in CKD patients. RISCAVID study, a study that sought to elucidate the relevance of known risk factors in hemodialysis, demonstrated the existence of a prognostic value of SC4D0L for the cardiovascular risk. Professor Cantaluppi will then present the preliminary and promising results on how an adsorptive dialysis membrane is able to significantly reduce levels of SC4D0L in CKD patients with a baseline value higher than prognostic one defined in RISCVID.

Dr. Masakane will talk about the clinical benefits of a new PMMA membrane, developed for an improved anti-thrombogenicity and finally Dr. Abe will present data from National Japanese Registry the possible effect on middle-long term comorbidities due to the use of different synthetic membranes.

Chair: Vincenzo Panichi (Italy)
Program:
- Chronic inflammation and cardiovascular risk: SC4D0L as a predictive marker of cardiovascular morbidity and mortality in CKD
  Vincenzo Panichi (Italy)
- Role of adsorptive membrane in the reduction of serum soluble CD40-Ligand (SC4D0L) levels: a new frontier in hemodialysis
  Vincenzo Cantaluppi (Italy)
- Clinical benefits of adsorptive membrane with the property of anti-thrombogenicity — Proposal for “human compatible dialysis” —
  Ikuto Masakane (Japan)
- Comparison of different synthetic dialyzer membranes on mortality in hemodialysis patients in Japan
  Masanori Abe (Japan)
TREATMENT ADVANCES TO THE PATHWAY OF ELIMINATION OF CHRONIC HCV INFECTION IN CKD PATIENTS

SUNDAY, 4 JUNE 2017
13:40 – 14:50
Room N117-118

CHAIR
Jose M. Morales
Professor of Medicine
Consultant Investigator in the Research Institute of Hospital Transplantation Society Madrid, Spain

FACULTY
Kosh Agarwal
Institute for Liver Studies
King’s College Hospital
London, UK

Niraj Desai
Assistant Professor of Surgery
Transplant Division
Johns Hopkins University
Baltimore, Maryland, USA

Michel Jadoul
Head, Department of Nephrology Cliniques Universitaires Saint-Luc
Université Catholique de Louvain Brussels, Belgium

LEADERSHIP • COMMITMENT • INNOVATION
More Than 30 Years of Innovation and Commitment to Patients With Chronic Hepatitis C

Please visit us at Booth #4030

Dear Colleague,

It gives us great pleasure to welcome you to this Vifor Fresenius Medical Care Renal Pharma-sponsored symposium, entitled Management of CKD-MBD: time for new concepts?

During this educational programme, we will initially discuss the evidence and rationale behind some key changes in the updated KDIGO guidelines for CKD-MBD. Despite the availability of guidelines, however, some challenges remain in the management of CKD-MBD in clinical practice and we will therefore then move on to consider several of these in more detail. Our second presentation will discuss potential approaches to improve the control of hyperphosphatemia in patients on dialysis – taking into consideration both physician and patient perspectives. Finally, we will review the available evidence regarding the impact of secondary hyperparathyroidism pre-dialysis, the role of modifiable risk factors such as hyperphosphatemia, hypocalcaemia and vitamin D deficiency, and the potential limitations of current treatment strategies.

This promises to be an engaging and informative programme and we encourage you to submit your questions for the Q&A session by completing the question cards provided and handing them to an organiser during the symposium.

Professor Markus Ketteler
Chair

Light refreshments will be provided prior to the symposium

Programme

18.45  Chair’s introduction: how new evidence is guiding the guidelines
       Markus Ketteler, Germany

18.55  Management of MBD on dialysis: how can we improve the control of hyperphosphatemia?
       Jürgen Floege, Germany

19.15  Treatment of MBD before reaching ESRD: what is the role of 25(OH)D?
       John Cunningham, UK

19.35  Q&A and meeting close
       Markus Ketteler, Germany
Long-term Dialysis Dependence after Acute Kidney Injury (AKI): the Health-Economic Impact

Program

Introduction and welcome
Choice of renal replacement therapy (RRT) modality for AKI: does it matter? Thomas Rimmelé
Cost implications of non-recovery of renal function after AKI John R. Prowle
Panel discussion and Q&A
Summary and close

Industry Symposium
Sunday 4 June 2017
18:45–19:45
Hall N107–108
IFEMA – Feria de Madrid

Refreshments will be provided

Scientific Chair
Claudio Ronco, Italy

Faculty
Thomas Rimmelé, France
John R. Prowle, UK

With the support of Baxter Healthcare SA
CARNITINE DEFICIENCY IN DIALYSIS: how can we identify the right patients?

Chair: Gianfranco Guarnieri
Department of Internal Medicine, Cattinara General Hospital, University of Trieste, Italy

Speakers: Ronald J.A. Wanders
Lab. Genetic Metabolic Diseases, University of Amsterdam, The Netherlands

Tim Ulinski
Department of Pediatric Nephrology, Armand Trusseau Hospital, APHP Paris, France

Overall, the evidence demonstrates that carnitine is essential to human health. Carnitine has several key roles, particularly in fatty acid β-oxidation and detoxification of resulting end products within the cell, as well as the removal of deleterious acyl-CoA species. The disturbance in carnitine homeostasis associated with haemodialysis treatment has been well described, with numerous studies demonstrating a significant reduction in endogenous L-carnitine concentrations in several patients undergoing long-term haemodialysis treatment. However, recent studies have established that the characteristics of dialysis-related carnitine deficiency are more complex, with haemodialysis not only associated with low endogenous L-carnitine concentrations, but also accumulation of acylcarnitines, in particular medium- and long-chain compounds due to their inefficient removal during the dialysis procedure. These alterations in carnitine pool composition have been implicated in a number of dialysis-related disorders including erythropoietin-resistant renal anemia, cardiovascular disease and muscle weakness. Some studies have reported that carnitine supplementation results in a significant reduction in erythropoietin dose requirements in patients with erythropoietin resistant anemia. Several haemodialysis patients can benefit from carnitine treatment.

How can we identify the patients who more likely will benefit from carnitine supplementation? In the first lecture, the disturbance carnitine deficiency and insufficiency will be focused and the support of metabolomics and acylcarnitine profiling in correct patient identification and prognosis will be reviewed and discussed.

Then carnitine treatment in dialysis patients will be also discussed with regard to clinical manifestations like anemia, cardiac disease, intradialytic hypotension, muscle weakness and with a particular focus on pediatrics.

REFERENCES
THREE TIMES A WEEK DIALYSIS MAY NOT BE ENOUGH.

More frequent home hemodialysis has been associated with clinical and quality of life benefits.

MORE FREQUENT HD IMPROVED OUTCOMES: THE WISH COMES TRUE AT HOME

PROGRAM
Moderators: Dr. Natalie Borman: Portsmouth UK and Pr. Maria Bajo, Madrid Spain

“NEW EUROPEAN EVIDENCE WITH HOME HD PATIENTS: 12 MONTHS FOLLOW-UP IN KIHDEy COHORT”
Dr. Sunita Nair, Shrewsbury UK

“MINERAL AND BONE DISORDERS AND SERUM PHOSPHORUS: WE CAN FREE BOTH DIET AND PILL BURDEN!”
Pr. Eric Goffin, Brussel Belgium

“LIVING MY WAY OF LIFE WITH HOME HD”
A NxStage Patient
Dear Colleague

It is with great pleasure that I welcome you to this Vifor Fresenius Medical Care Renal Pharma-sponsored symposium, entitled **Optimizing RAASI therapy in cardio-renal patients through hyperkalaemia management**.

During this symposium I will be joined by an internationally renowned faculty to discuss a common dilemma faced by physicians treating cardio-renal patients with RAASI therapy: how does hyperkalaemia change the way a RAASI should be prescribed – should it be prescribed at a reduced dose, or should treatment be stopped? We will start with an overview of the benefits of RAASI treatment from a cardiologist’s perspective and from a nephrologist’s perspective. From there, we will move on to discuss the current limitations of hyperkalaemia management and how these limitations create a catch-22 situation that prevents optimization of RAASI therapy. Finally, we will consider how novel potassium binders can control hyperkalaemia and enable the use of RAASI therapy for the ultimate benefit of cardio-renal patients.

This promises to be an informative and engaging educational session. I encourage you to submit your questions for the Q&A session by completing the question cards provided and handing them to an organizer during the symposium.

Professor Angel de Francisco
Chair

RAASI, renin-angiotensin-aldosterone system inhibitor

www.era-edta2017.org
Remote Patient Management (RPM) in Home Dialysis: Changing the Paradigm of Care

Program start time: 13:45
Program duration: 60 minutes

Program

- Introduction and welcome
- Role of RPM in reducing barriers to use of home dialysis
  Dominik Alscher
- Evaluating the potential impact of RPM in improving clinical outcomes in the pediatric ESRD population
  Franz Schaefer
- Spanish experience with RPM in automated peritoneal dialysis
  Emilio Sánchez
- Panel discussion and Q&A
- Summary and close

Scientific Chair
Miguel Pérez Fontán, Spain

Faculty
Dominik Alscher, Germany
Franz Schaefer, Germany
Emilio Sánchez, Spain

Lunch will be provided at 13:30

With the support of Baxter Healthcare SA
Dear Delegate,

It is our pleasure to invite you to attend the Alexion-sponsored satellite symposium at the 54th congress of the European Renal Association and European Dialysis and Transplant Association.

**Distinguishing aHUS from pregnancy- and hypertension-associated thrombotic microangiopathies**

During this symposium, we will:

- Discuss the complexities of reaching a differential diagnosis of atypical haemolytic uraemic syndrome (aHUS) in adults presenting with thrombotic microangiopathy (TMA)
- Focus specifically on cases of malignant hypertension- and pregnancy-associated TMA and the relationship to aHUS
- Present novel data on the role of complement abnormalities
- Ask the panel of experts to provide their clinical and practical advice on how to overcome the diagnostic challenges

Additionally, we will be hosting an open Q&A panel session, enabling an exchange of ideas on the effective identification and management of these patients.

We look forward to your active participation in this educational meeting.

**Symposium information**

Monday 5 June 2017, 13:30–15:00
Hall N101–102, IFEMA Feria de Madrid – North Congress Centre

**Programme**

<table>
<thead>
<tr>
<th>Programme</th>
<th>Chair/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and introduction</td>
<td>Manuel Praga (Madrid, Spain)</td>
</tr>
<tr>
<td>The challenge of diagnosing aHUS</td>
<td></td>
</tr>
<tr>
<td>Complicated pregnancies and the role of the complement</td>
<td>Seppo Meri (Helsinki, Finland)</td>
</tr>
<tr>
<td>Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities</td>
<td>Pieter van Paassen (Maastricht, Netherlands)</td>
</tr>
<tr>
<td>Insights from the clinic – challenging cases</td>
<td>Jan Menne (Hannover, Germany)</td>
</tr>
<tr>
<td>Q&amp;A and concluding remarks</td>
<td>Manuel Praga</td>
</tr>
</tbody>
</table>

Please visit the Alexion booth in the industry exhibition area
Learning objectives

The objectives of this educational event are to help delegates understand:

1) The current epidemiological trends, threats and treatments in patients with chronic kidney disease (CKD)
2) The mode of action, renal safety and renal effects of SGLT2 inhibitors in patients with Type 2 diabetes and healthy individuals
3) The potential roles and mechanisms of SGLT2 inhibitors in CKD

Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–14:00</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14:00–14:10</td>
<td>Chair’s Introduction</td>
<td>Per-Henrik Groop (Finland)</td>
</tr>
<tr>
<td>14:10–14:30</td>
<td>SGLT2 Inhibitors: Building a Case for Evidence-based Kidney Protection</td>
<td>Hiddo Lambers-Heerspink (Netherlands)</td>
</tr>
<tr>
<td>14:30–14:50</td>
<td>Renal Effects of SGLT2 Inhibitors</td>
<td>Paola Fioretto (Italy)</td>
</tr>
<tr>
<td>14:50–15:00</td>
<td>Panel Q&amp;A / Discussion</td>
<td>All</td>
</tr>
</tbody>
</table>
A PROMPT START FOR A LONG-LASTING EFFECT

THE CASE FOR FABRY DISEASE

Chair: José-Vicente Torregrosa, Spain

SYMPOSIUM
5th June 2017 at 13:30 – 15:00
Hall 10.B

Lunch will be provided

AGENDA AND FACULTY

Welcome and Introduction
José-Vicente Torregrosa, Spain

The kidney: is inflammation rare in rare diseases?
Sandro Feriozzi, Italy

Putting the patient first: what are the advantages of enzyme replacement therapy?
Christoph Wanner, Germany

The importance of prompt treatment initiation in Fabry disease
Derralynn Hughes, UK

Q&A
All

This scientific programme will include information about a Shire-promoted product.
INTSP/C-APROM/REP/16/0019d; 02/2017
Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?

CO-CHAIRMEN
Carmine Zoccali, MD – CNR-IFC, Clinical Epidemiology of Renal Diseases and Hypertension, Reggio Calabria, Italy
Vincent M Brandenburg, MD – University Hospital RWTH Aachen, Germany

AGENDA
13:45 – 13:50 Introduction
Vincent M Brandenburg, MD – Aachen, Germany
13:50 – 14:05 The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?
Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain
14:05 – 14:20 Epigenetics as a novel strategy in cardiovascular and renal risk reduction: A closer look at BET as pathway for inhibition
Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain
14:20 – 14:40 BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?
Kamyar Kalantar-Zadeh, MD – UC Irvine School of Medicine, Irvine, Ca, USA
14:40 – 14:45 Discussion & summary
Carmine Zoccali, MD – Reggio Calabria, Italy

EBAC ACCREDITED SYMPOSIUM TO BE HELD DURING ERA EDTA 2017, MADRID, SPAIN

MONDAY, 5 JUNE 2017, 13:45 – 14:45 HRS • SALA RETIRO

Supported by an unrestricted educational grant from Resverlogix.

“In compliance with EBAC guidelines, all speakers/Chairpersons participating in this programme have disclosed all potential conflicts of interest which might cause a bias in the presentations. The Organising Committee Course Director is responsible for ensuring that all potential conflicts of interest relevant to the course are disclosed to the audience prior to the CME activities.”
AGENDA

Chair and introductory talk
Olivier Devuyst, M.D., Ph.D.,
University of Zurich, Switzerland and Saint-Luc Academic Hospital, UCL Medical School, Belgium

- Mechanisms for dehydration associated kidney disease
  Richard J. Johnson, M.D.,
  University of Colorado, USA

- Can water intake prevent chronic kidney disease?
  William Clark, Ph.D.,
  University of Western Ontario, London, Canada

Lunchboxes will be available
Monday 5th June 2017
Lunchtime Symposium, 13:30-14:30
Sala Colón, IFEMA Feria de Madrid

We look forward to seeing you at our booth number 6.005
Lunch boxes will be provided at the start of the symposium

Chair: Dr Roman-Ulrich Müller

Programme

13:30  Chair’s Welcome and Introduction
Dr Roman-Ulrich Müller
University of Cologne, Germany

13:35  Tolvaptan: what the evidence tells us
Dr Roman-Ulrich Müller
Germany

13:50  Tolvaptan: real-world experience
Prof Ron Gansevoort
University Medical Center Groningen, The Netherlands

14:10  Tolvaptan: sharing experience from the clinic
Dr Lukas Foggensteiner
University Hospitals Birmingham NHS Trust, UK

14:30  Closing Remarks
Dr Roman-Ulrich Müller
Germany

Prescribing information for tolvaptan can be found at
New biocompatible HDF membrane to enable max substitution for sensitive patients

→ Welcome and introduction
  Prof. Dr. Rafael Selgas
  Nephrology Department, Hospital General Universitario La Paz, Madrid, Spain

→ Comparison of old versus new generation Cellulose Triacetate membrane in HD and HDF treatments
  Dr. Francisco Maduell
  Nephrology Department, Hospital Clinic Barcelona, Barcelona, Spain

→ Biocompatible characteristics of newly developed smooth surface membrane
  Associate Prof. Dr. Tadashi Tomo
  Clinical Engineering Research Center, Faculty of Medicine, Oita University, Oita, Japan

BECAUSE EVERY LIFE DESERVES AFFORDABLE CARE